medicaid glp-1 covers meds for obesity in just 13 states, analysis finds California Ends Medicaid Coverage of

According to the SURPASS program, which included five studies, researchers reported that a weekly dose of tirzepatide at 15 mg significantly reduced systolic blood pressure by as much as 12.6 mm Hg [97]

M., Gratzl, S., et al

Provider-Guided Weight-Loss Care Get provider-guided treatment, practical support, and tools to help you navigate appetite changes, meals, and progress along the way

Learn more in our complete retatrutide research guide

Sardu et al

Considering the widespread expression of GLP-1 receptors in the brain, the authors recommend that future studies should focus on identifying the key neurocircuits involved in mediating the effects of GLP-1 receptor agonists on substance use disorder, as well as determine the specific patient subtypes who are most likely to benefit from these treatments